Inhibikase TherapeuticsIKT
13F holders, Q4 2024 (December 31)At the end of Q4 2024, 31 institutions reported holding Inhibikase Therapeutics Inc. (IKT) in their 13F filings, up 20 from Q3 2024. 23 opened new positions and 3 sold out. The largest holders were Sands Capital Alternatives, LLC ($35.6M), Soleus Capital Management, L.P. ($20.6M) and Fairmount Funds Management LLC ($19.9M). One famous investor held it Israel Englander (0.0% of Millennium Management's portfolio).
- Company
- Inhibikase Therapeutics Inc.
- CUSIP
- 45719W205
- Latest filing quarter
- Q2 2026
History
Number of 13F holders
Total Exit/New Position Q3 2024 → Q4 2024
| Institutions | Total Value | |
|---|---|---|
| New Positions | 23 | $151.7M |
| Exits | 3 | $846K |
All 13F filers, Q3 2024 → Q4 2024: 49,849,555 shares bought and 650,479 shares sold, net +49,199,076 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 31 holders
| Sands Capital Alternatives, LLC | 7.74% | New | 10,950,000 | $35.6M |
| Soleus Capital Management, L.P. | 1.56% | New | 6,325,000 | $20.6M |
| Fairmount Funds Management LLC | 1.98% | New | 6,125,000 | $19.9M |
| Commodore Capital LP | 1.41% | New | 5,925,000 | $19.3M |
| Perceptive Advisors LLC | 0.54% | New | 5,925,000 | $19.3M |
| ADAR1 Capital Management, LLC | 3.53% | New | 5,103,005 | $16.6M |
| Vanguard Group Inc. | 0.00% | Add +16873.5% | 2,838,645 | $9.2M |
| Nantahala Capital Management, LLC | 0.50% | New | 2,190,000 | $7.1M |
| Blackstone Inc. | 0.03% | New | 2,070,684 | $6.7M |
| Stonepine Capital Management, LLC | 2.97% | New | 1,132,388 | $3.7M |
| BlackRock, Inc. | 0.00% | New | 335,460 | $1.1M |
| Geode Capital Management, LLC | 0.00% | Add +544.9% | 322,878 | $1.0M |
| Millennium Management | 0.00% | New | 142,209 | $462K |
| Blair William & Co. | 0.00% | Add +7.0% | 134,953 | $439K |
| Barclays PLC | 0.00% | New | 84,000 | $273K |
| Citigroup Inc. | 0.00% | New | 77,100 | $251K |
| Northern Trust Corp. | 0.00% | New | 64,011 | $208K |
| OMERS ADMINISTRATION Corp | 0.00% | New | 54,600 | $177K |
| HRT Financial LP | 0.00% | New | 46,416 | $150K |
| Goldman Sachs Group Inc. | 0.00% | New | 43,952 | $143K |
| State Street Corp. | 0.00% | Add +315.4% | 41,884 | $136K |
| Squarepoint Ops LLC | 0.00% | New | 28,411 | $92K |
| UBS Group AG | 0.00% | Add +464.9% | 27,526 | $89K |
| Caxton Corp. | 0.32% | New | 16,393 | $53K |
| Alpine Global Management, LLC | 0.02% | New | 14,842 | $48K |
| Jefferies Financial Group Inc. | 0.00% | New | 14,800 | $48K |
| Stifel Financial Corp. | 0.00% | New | 13,129 | $43K |
| Morgan Stanley | 0.00% | Add +337.7% | 7,296 | $24K |
| Bank of America Corp. | 0.00% | Add +8407.5% | 4,509 | $15K |
| Wells Fargo & Company | 0.00% | No change | 167 | $543 |
| Synergy Asset Management, LLC | 0.00% | New | 50 | $65 |
"% of holder's portfolio" is IKT's weight in each manager's 13F, not the share of Inhibikase Therapeutics Inc. the manager owns.